Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy
| Autor: | Martin D. Valentine, Ira D. Lawrence, Anne Kagey-Sobotka, Robert H. Hamilton, Lawrence M. Lichtenstein, David B.K. Golden |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Risk Allergen immunotherapy Allergy medicine.medical_treatment Immunology Insect Bites and Stings Wasp Venoms Venom Immunotherapy Middle Aged Biology medicine.disease complex mixtures Insect sting allergy Bee Venoms Sting Desensitization Immunologic Immunoglobulin G medicine Humans Immunology and Allergy Anaphylaxis Yellow jacket |
| Zdroj: | Journal of Allergy and Clinical Immunology. 90:386-393 |
| ISSN: | 0091-6749 |
| DOI: | 10.1016/s0091-6749(05)80019-3 |
| Popis: | Allergen immunotherapy is associated with a significant increase of specific IgG antibodies that have been suggested as a mechanism of action and as a marker of efficacy for immunotherapy. The value of venom-specific IgG antibody determinations as a measure of clinical protection against sting anaphylaxis has been difficult to prove in individual patients. We performed 211 insect sting challenges in 109 patients over a 4-year period to determine the significance of venom IgG levels 3 micrograms/ml or lower. Systemic symptoms occurred in only 1.6% of those with venom IgG more than 3 micrograms/ml, but in 16% of those with less than 3 micrograms/ml IgG, and notably in 26% of patients with low venom IgG who had received less than 4 years of treatment. The venom IgG level had no predictive value in patients who had received more than 4 years of therapy. Honeybee sting data were inconclusive because of the small number of subjects. We conclude that low venom-specific IgG levels are associated with an elevated risk of treatment failure during the first 4 years of immunotherapy with yellow jacket or mixed vespid venoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|